Patents by Inventor Joseph M. Carroll
Joseph M. Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220008889Abstract: A change of state of weed seeds to having reduced germination viability in one minute by illuminating a seed in a processing theater to achieve at least one of 0.66 J/cm2 cumulative illumination energy, and 0.06 W/cm2 irradiance, of at least one of an Indigo Region Illumination Distribution (IRID), and Medium Wavelength Infrared (MWIR) radiation, preferably 2-8 microns, with no high energy transfers, scalding, heat shock, cooking or incineration. The MWIR radiation from heated borosilicate glass or glass powder at just under 500 C offered a peak MWIR emission of 3.75 microns, and was unexpectedly effective, and can be used in a radiant and transmissive weed seed accumulator transport belt. The process can be incorporated into a harvester combine to convert a tailings flow prior to discharge on an agricultural field. An illuminated harvest combine using an illuminator according to the invention allows reduction of the weed seed bank.Type: ApplicationFiled: July 7, 2020Publication date: January 13, 2022Inventors: Jonathan A. JACKSON, Christopher J. HOFFMAN, Norman E. NOVOTNEY, Joseph M. CARROLL, Patrick A. JACKSON, Remigio PERALES, Mark J. ELTING
-
Patent number: 9059963Abstract: The method and system allow an owner of a collection of vehicles, such as a classic automobile collection, to upload and store public and private vehicle information. Public vehicle information is accessible by other users of the system desiring to learn about the user's vehicle collection. Private vehicle information is available only to those users whom the vehicle owner designates should receive an evaluation file containing the private information.Type: GrantFiled: May 3, 2013Date of Patent: June 16, 2015Assignee: MyClassicGarage, LLCInventor: Joseph M. Carroll
-
Publication number: 20130332578Abstract: The invention relates to a computerized method and system for storing and selectively sharing information relating to vehicles. The system allows an owner of a collection of vehicles, such as a classic automobile collection, to upload and store public and private vehicle information. Public vehicle information is accessible by other users of the system desiring to learn about the user's vehicle collection. Private vehicle information is available only to those users whom the vehicle owner designates should receive an evaluation file containing the private information.Type: ApplicationFiled: May 3, 2013Publication date: December 12, 2013Applicant: MyClassicGarage, LLCInventor: Joseph M. Carroll
-
Publication number: 20110165147Abstract: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: March 1, 2011Publication date: July 7, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Maria A. Glucksmann, Inmaculada Silos-Santiago, Joseph M. Carroll, Katherine M. Galvin
-
Publication number: 20100150901Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.Type: ApplicationFiled: October 22, 2008Publication date: June 17, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A.J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
-
Publication number: 20100136010Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 21, 2008Publication date: June 3, 2010Inventors: Rosana Kappeller-Libermann, David White, Keith E. Robison, Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
-
Publication number: 20100098713Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: September 15, 2009Publication date: April 22, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Welch, Rajasekhar Bandaru
-
Publication number: 20090226451Abstract: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: April 28, 2009Publication date: September 10, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Maria A. Glucksmann, Inmaculada Silos-Santiago, Joseph M. Carroll, Katherine M. Galvin
-
Publication number: 20090191147Abstract: The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.Type: ApplicationFiled: August 27, 2008Publication date: July 30, 2009Applicant: Genetics Institute, LLCInventors: James Keith, Joseph M. Carroll, Jordan S. Pober
-
Publication number: 20090130681Abstract: The invention provides isolated nucleic acids molecules, designated 21132 nucleic acid molecules, which encode novel GPCR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21132 gene has been introduced or disrupted. The invention still further provides isolated 21132 proteins, fusion proteins, antigenic peptides and anti-21132 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: August 27, 2008Publication date: May 21, 2009Inventor: Joseph M. Carroll
-
Patent number: 7485308Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.Type: GrantFiled: July 26, 2006Date of Patent: February 3, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A. J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
-
Publication number: 20090024881Abstract: A method of evaluating and acquiring charged-off debt portfolios that includes providing a seller with an assessment mechanism for the debt portfolio, receiving from the seller a proposed price and debt account information for the debt portfolio based on the use of the assessment mechanism, and determining whether to acquire the debt portfolio based on the use of the assessment mechanism. The method may include a computer implemented method of assessing a portfolio of debt accounts using an assessment mechanism that includes collecting debt account information, storing the debt account information in an account record, creating a debt portfolio, and valuating the debt portfolio.Type: ApplicationFiled: July 10, 2008Publication date: January 22, 2009Applicant: HUDSON & KEYSE, L.L.C.Inventors: Joseph M. CARROLL, Francis A. CARROLL, Timothy M. NOVAK
-
Patent number: 7474795Abstract: The present technique selectively handles image data, which is decomposed into a plurality of resolution levels. In one embodiment, an image resolution suitable for display in a desired viewport is selected via an iterative process including determining whether scaling of one of the different image resolutions of the plurality of different image resolutions by a predetermined scaling threshold would result in a scaled image resolution that is less than or equal to the resolution of the desired viewport. A portion of the plurality of data sets may be selectively requested for recomposition of the image at the image resolution. Additional systems, methods, and devices for handling image data are also disclosed.Type: GrantFiled: May 29, 2007Date of Patent: January 6, 2009Assignee: GE Medical Systems Information Technologies, Inc.Inventors: Saad A. Sirohey, Robert D. Barnes, Joseph M. Carroll
-
Publication number: 20080234468Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 31, 2007Publication date: September 25, 2008Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
-
Patent number: 7351566Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 5, 2006Date of Patent: April 1, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
-
Patent number: 7250262Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders.Type: GrantFiled: January 28, 2003Date of Patent: July 31, 2007Assignee: Bayerhealth Care AGInventors: Joseph M. Carroll, Aileen Healy, Nadine S. Weich, Louise M. Kelly
-
Patent number: 7236637Abstract: The present technique selectively handles image data, which is decomposed into a plurality of resolution levels. The image data may be retrieved in order of progressively higher resolution levels for display in a viewport. Initially, the image data may be displayed in the viewport at a relatively lower one of the plurality of resolution levels. As a user desires higher resolution displays of all or part of the image, one or more of the progressively higher resolution levels may be retrieved and scaled to fit the viewport. Accordingly, the present technique handles the data more efficiently by accessing the image data in blocks corresponding to the plurality of resolution levels, rather than accessing the entirety of the image data. A scaling threshold also can be used to signal the need for a next higher level of the plurality of resolution levels.Type: GrantFiled: November 21, 2001Date of Patent: June 26, 2007Assignee: GE Medical Systems Information Technologies, Inc.Inventors: Saad A. Sirohey, Robert D. Barnes, Joseph M. Carroll
-
Patent number: 7098015Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 11, 2003Date of Patent: August 29, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
-
Patent number: 7094587Abstract: The invention provides isolated nucleic acids molecules, designated 16002 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16002 gene has been introduced or disrupted. The invention still further provides isolated 16002 proteins, fusion proteins, antigenic peptides and anti-16002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 18, 2003Date of Patent: August 22, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Weich, Rajasekhar Bandaru
-
Patent number: 7045505Abstract: Isolated nucleic acids molecules, designated 69039 nucleic acid molecules, which encode novel Na+/Ca2+ exchanger members, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69039 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69039 gene has been introduced or disrupted. Isolated 69039 proteins, fusion proteins, antigenic peptides and anti-69039 antibodies are also disclosed. The invention further provides methods of treating, preventing and diagnosing hematopoietic and neurological disorders.Type: GrantFiled: September 27, 2002Date of Patent: May 16, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventor: Joseph M. Carroll